Hussman Strategic Advisors Inc. Takes Position in DaVita Inc. $DVA

Hussman Strategic Advisors Inc. purchased a new stake in DaVita Inc. (NYSE:DVA) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 8,400 shares of the company’s stock, valued at approximately $1,116,000.

A number of other hedge funds also recently bought and sold shares of DVA. KBC Group NV increased its position in shares of DaVita by 38.7% in the second quarter. KBC Group NV now owns 374,749 shares of the company’s stock valued at $53,383,000 after buying an additional 104,554 shares in the last quarter. Nordea Investment Management AB grew its stake in DaVita by 1.8% in the 3rd quarter. Nordea Investment Management AB now owns 286,585 shares of the company’s stock valued at $37,864,000 after acquiring an additional 5,193 shares during the period. Man Group plc increased its holdings in DaVita by 1,608.6% in the 2nd quarter. Man Group plc now owns 285,809 shares of the company’s stock worth $40,713,000 after acquiring an additional 269,081 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its position in DaVita by 132.1% during the second quarter. Arrowstreet Capital Limited Partnership now owns 264,084 shares of the company’s stock worth $37,619,000 after acquiring an additional 150,318 shares during the period. Finally, Worldquant Millennium Advisors LLC raised its position in DaVita by 49.1% during the second quarter. Worldquant Millennium Advisors LLC now owns 257,845 shares of the company’s stock worth $36,730,000 after acquiring an additional 84,859 shares during the period. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Stock Performance

NYSE:DVA opened at $105.86 on Thursday. DaVita Inc. has a one year low of $101.00 and a one year high of $179.60. The stock has a market cap of $7.47 billion, a PE ratio of 10.90, a P/E/G ratio of 0.65 and a beta of 0.99. The stock has a 50 day moving average price of $113.97 and a 200 day moving average price of $125.67.

DaVita (NYSE:DVA) last released its quarterly earnings data on Wednesday, October 29th. The company reported $2.51 earnings per share for the quarter, missing analysts’ consensus estimates of $3.17 by ($0.66). DaVita had a negative return on equity of 13,370.89% and a net margin of 5.80%.The company had revenue of $3.42 billion for the quarter, compared to analyst estimates of $3.43 billion. During the same period last year, the firm posted $2.59 EPS. The business’s quarterly revenue was up 4.8% on a year-over-year basis. As a group, analysts predict that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on DVA shares. Zacks Research raised shares of DaVita from a “strong sell” rating to a “hold” rating in a research note on Friday, November 28th. Wall Street Zen cut DaVita from a “buy” rating to a “hold” rating in a report on Saturday, October 11th. Weiss Ratings reissued a “hold (c)” rating on shares of DaVita in a report on Monday, December 29th. Barclays lowered their price target on DaVita from $149.00 to $143.00 and set an “equal weight” rating on the stock in a research note on Thursday, October 30th. Finally, TD Cowen reissued a “hold” rating on shares of DaVita in a research note on Monday, November 3rd. One research analyst has rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $145.60.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.